The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
p28, an Anionic Cell-Penetrating Peptide, Increases the Activity of Wild Type and Mutated p53 without Altering Its Conformation
Abstract
p28, a cell penetrating peptide, binds to the DNA binding domain (DBD) of p53, inducing a post-translational increase in intracellular levels of wild type and mutant p53 activating pathways that inhibit cancer cell proliferation at G2/M. Cancer cells respond to p28 with an increase in p53 activity, except when mutations either alter DNA contact or completely unfold the DBD. The increase in p53 activity is accompanied by a significant reduction in the level of the E3 ligase COP1, with no alteration in p53 conformation. This suggests p28 can activate p53 over a wide range of conformational mutations by inhibiting the binding of COP1 to p53.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p28 inhibits the interaction between the E3 ligase COP1 and p53,517 improves the posttranslational stability of p53, and increases p53 protein expression in various p53 wild-type or mutated tumor cell lines.518,519”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [518]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Research works printed but not linked: 44
- Prives C., 1999, J. Pathol., 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
- Vogelstein B., 2000, Nature, 408, 307, 10.1038/35042675 · DOI · Paper page
- Blagosklonny M. V., 1997, Oncogene, 15, 1889, 10.1038/sj.onc.1201374 · doi:10.1038/sj.onc.1201374
- Freed-Pastor W. A., 2012, Genes Dev., 26, 1268, 10.1101/gad.190678.112 · DOI · Paper page
- Bullock A. N., 2001, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
- Muller P., 2008, Oncogene, 27, 3371, 10.1038/sj.onc.1211010 · DOI · Paper page
- Wu X., 1993, Genes Dev., 7, 1126, 10.1101/gad.7.7a.1126 · DOI · Paper page
- Ashcroft M., 2000, Mol. Cell. Biol., 20, 3224, 10.1128/MCB.20.9.3224-3233.2000 · DOI · Paper page
- Leng R. P., 2003, Cell, 112, 779, 10.1016/S0092-8674(03)00193-4 · DOI · Paper page
- Dornan D., 2004, Nature, 429, 86, 10.1038/nature02514 · DOI · Paper page
- Dornan D., 2006, Science, 313, 1122, 10.1126/science.1127335 · DOI
- Su C. H., 2011, Cancer Res., 71, 884, 10.1158/0008-5472.CAN-10-2518 · doi:10.1158/0008-5472.can-10-2518
- Dornan D., 2004, Cancer Res., 64, 7226, 10.1158/0008-5472.CAN-04-2601 · DOI
- Vu B. T., 2011, Curr. Top. Microbiol. Immunol., 348, 151
- Blagosklonny M. V., 2005, Cancer Res., 65, 7386, 10.1158/0008-5472.CAN-04-3433 · DOI
- Li D., 2011, Cell Death Differ., 18, 1904, 10.1038/cdd.2011.71 · DOI · Paper page
- Bykov V. J., 2005, J. Biol. Chem., 280, 30384, 10.1074/jbc.M501664200 · DOI · Paper page
- Taylor B. N., 2009, Cancer Res., 69, 537, 10.1158/0008-5472.CAN-08-2932 · DOI · Paper page
- Yamada T., 2009, Mol. Cancer Ther., 8, 2947, 10.1158/1535-7163.MCT-09-0444 · DOI
- Jia L., 2011, Cancer Chemother. Pharmacol., 68, 513, 10.1007/s00280-010-1518-3 · DOI
- Bizzarri A. R., 2011, Int. J. Nanomed., 6, 3011, 10.2147/IJN.S26155 · DOI · Paper page
- Yamada T., 2013, Br. J. Cancer, 108, 2495, 10.1038/bjc.2013.266 · DOI · Paper page
- Kichina J. V., 2003, Oncogene, 22, 4911, 10.1038/sj.onc.1206741 · DOI
- De Grandis V., 2007, J. Mol. Recognit., 20, 215, 10.1002/jmr.840 · DOI
- Bizzarri A. R., 2009, J. Mol. Recognit., 22, 506, 10.1002/jmr.975 · DOI
- Kozakov D., 2010, Proteins, 78, 3124, 10.1002/prot.22835 · DOI · Paper page
- Zhang C., 1997, J. Mol. Biol., 267, 707, 10.1006/jmbi.1996.0859 · DOI · Paper page
- Camacho C. J., 2000, Biophys. J., 78, 1094, 10.1016/S0006-3495(00)76668-9 · DOI
- Reynolds C., 2009, Bioinformatics, 25, 413, 10.1093/bioinformatics/btn584 · DOI · Paper page
- Yamada T., 2002, Proc. Natl. Acad. Sci. U.S.A., 99, 14098, 10.1073/pnas.222539699 · DOI · Paper page
- Punj V., 2004, Oncogene, 23, 2367, 10.1038/sj.onc.1207376 · DOI · Paper page
- Wiman K. G., 1991, Oncogene, 6, 1633
- Joerger A. C., 2007, Oncogene, 26, 2226, 10.1038/sj.onc.1210291 · DOI · Paper page
- Su Y., 2010, Biochemistry, 49, 6009, 10.1021/bi100642n · DOI
- Liu S., 2009, BMC Cancer, 9, 162, 10.1186/1471-2407-9-162 · DOI
- Vassilev L. T., 2004, Science, 303, 844, 10.1126/science.1092472 · DOI · Paper page
- Tovar C., 2013, Cancer Res., 73, 2587, 10.1158/0008-5472.CAN-12-2807 · DOI · Paper page
- Monti P., 2011, Mol. Cancer Res., 9, 271, 10.1158/1541-7786.MCR-10-0496 · DOI
- Lee M. K., 2012, Cancer Cell, 22, 751, 10.1016/j.ccr.2012.10.022 · DOI
- Vaughan C. A., 2012, Genes Cancer, 3, 491, 10.1177/1947601912462719 · DOI
- Bourdon J. C., 2007, Br. J. Cancer, 97, 277, 10.1038/sj.bjc.6603886 · DOI · Paper page
- Khoury M. P., 2010, Cold Spring Harbor Perspect. Biol., 2, a000927, 10.1101/cshperspect.a000927 · DOI · Paper page
- Aoubala M., 2010, Breast Cancer Res., 12, P8, 10.1186/bcr2505 · doi:10.1186/bcr2505
- Warso M. A., 2013, Br. J. Cancer, 108, 1061, 10.1038/bjc.2013.74 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Cell Penetrating Peptides as Molecular Carriers for Anti-Cancer Agents
Borrelli, A., Tornesello, A., Tornesello, M., & Buonaguro, F. (2018) · Molecules · doi:10.3390/molecules23020295 · Cited by 295
Advances and prospects of cell-penetrating peptides in tumor immunotherapy
Yang, D., Liu, B., & Sha, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-86130-8 · Cited by 31
Metadata
- Authors
- Yamada, T., Das Gupta, T. K., & Beattie, C. W.
- Affiliations
- Department of Surgery, Division of Surgical Oncology, University of Illinois at Chicago College of Medicine, 840 South Wood Street, Suite 618, Chicago, Illinois 60612, United States
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-08-16
- Volume
- 10
- Issue
- 9
- Pages
- 3375-3383
- ISSN
- 1543-8384
- 1543-8392
- Cited by
- 51
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.